Nuvalent slides as biotech risk-off hits, after ASCO catalyst and April FDA filing
Nuvalent shares fell 3.01% to $104.69 on April 24, 2026 as biotech trading weakened and investors took profits after recent catalyst headlines. The pullback follows an April 21 announcement of an ASCO 2026 oral presentation for pivotal ALKOVE-1 neladalkib data and an April 7 SEC filing disclosing an FDA NDA submission for neladalkib in TKI pre-treated ALK+ NSCLC.
1. What’s happening in the stock
Nuvalent (NUVL) traded lower Friday, down about 3% to $104.69, in a move that looked more like a risk-off pullback than a company-specific shock. With no fresh Nuvalent press release dated April 24, investors appeared to fade the recent run and reduce exposure to higher-beta clinical-stage biotech names as broader trading turned cautious.
2. The most recent Nuvalent-specific catalysts investors are digesting
Earlier this week, Nuvalent announced it will present pivotal data from the global ALKOVE-1 Phase 1/2 trial of neladalkib in TKI pre-treated advanced ALK-positive non-small cell lung cancer in an oral session at the 2026 ASCO Annual Meeting (May 29–June 2, 2026, Chicago), alongside preliminary data in TKI-naïve patients. That kind of upcoming readout can drive pre-event positioning—and then short-term profit-taking when the market tone sours.
Separately, an April 7, 2026 Form 8-K disclosed that Nuvalent submitted a New Drug Application to the FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC, a major regulatory milestone that can also contribute to recent strength and subsequent consolidation.
3. What to watch next
Key near-term focus is the ASCO presentation window (May 29–June 2, 2026) and any additional details released with the abstract, slides, or subsequent company communications. Traders will also monitor whether the FDA accepts the neladalkib NDA and sets a review timeline, as any regulatory updates could quickly override today’s tape-driven pullback.